| Date Filed | Type | Description |
| 02/10/2014 |
SC 13G/A
| AQR CAPITAL MANAGEMENT LLC reports a 0% stake in Complete Genomics, Inc. |
| 03/28/2013 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)] |
| 03/21/2013 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 03/19/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 03/19/2013 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement |
| 03/19/2013 |
8-K
| Quarterly results |
| 03/18/2013 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| 03/18/2013 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities |
| 03/15/2013 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 03/15/2013 |
SC 13D/A
| BGI-SHENZHEN reports a 88.4% stake in COMPLETE GENOMICS, INC. |
| 03/12/2013 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
| 03/04/2013 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
| 01/07/2013 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
| 11/26/2012 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
| 11/09/2012 |
10-Q
| Quarterly Report for the period ended September 30, 2012 |
| 11/09/2012 |
8-K
| Quarterly results |
| 11/02/2012 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
| 10/19/2012 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
| 10/09/2012 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
| 09/27/2012 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
| 09/25/2012 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements |
| 09/25/2012 |
SC 13D
| BGI-SHENZHEN reports a 17.7% stake in § 240. Complete Genomics, Inc. |
| 09/25/2012 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party |
| 09/20/2012 |
SC 13D/A
| Form SC 13D - General statement of acquisition of beneficial ownership [amend] |
| 09/17/2012 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer |
| 09/17/2012 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party |
| 09/17/2012 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Agreement and Plan of Merger, by and among BGI-Shenzhen, Beta Acquisition Corporation and Complete Genomics, Inc",
"Tender and Support Agreement, by and among BGI-Shenzhen, Beta Acquisition Corporation, Clifford A. Reid, C. Thomas Caskey, Lewis J. Shuster, Charles P. Waite, Jr., Robert T. Wall, A. W. Homan, Ajay Bansal, Keith Raffel, Radoje T. Drmanac, OVP Venture Partners (and affiliated entities) and Essex Woodlands Health Ventures (and affiliated entities)",
"Convertible Subordinated Promissory Note, by and among BGI-Shenzhen, BGI-HONGKONG Co., Limited and Complete Genomics, Inc",
"Amendment to Loan and Security Agreement, by and between Oxford Finance LLC and Complete Genomics, Inc",
"Complete Genomics and BGI-Shenzhen Announce Definitive Agreement to Merge ~ Combination will create a global innovator in whole human genomic sequencing ~ Mountain View, CA and Shenzhen, China — Sept. 17, 2012 - Complete Genomics, Inc. , an innovative leader in whole human genomic sequencing, and BGI-Shenzhen , a leading international genomics company based in Shenzhen, China, today announced that they have entered into a definitive merger agreement. Through this agreement, a wholly-owned U.S. subsidiary of BGI will launch a tender offer to purchase all outstanding shares of common stock of Complete for $3.15 per share in cash, without interest. This price represents approximately a 54% premium to the $2.04 closing price per share of Complete common stock on June 4, 2012, the last trading ..." |
|
| 09/17/2012 |
GN
| Complete Genomics and BGI-Shenzhen Announce Definitive Agreement to Merge |
| 09/06/2012 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/09/2012 |
10-Q
| Quarterly Report for the period ended June 30, 2012 |
| 08/02/2012 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/19/2012 |
SC 13D/A
| Form SC 13D - General statement of acquisition of beneficial ownership [amend] |
| 06/25/2012 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 06/06/2012 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|